RECRUITING Phase 3 ClinicalTrials.gov

Thrombolysis in Factor Xa-inhibitors Trial

Sponsor: Guri Hagberg • ClinicalTrials.gov ID: NCT06878066

Registry updated: 2026-09-23

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

This study looks at whether stroke patients who take FXa inhibitors (a type of blood thinner) can safely receive clot-busting treatment (IVT). IVT is a common emergency treatment for stroke, but current guidelines say it should not be given to people who have taken FXa inhibitors in the last 48 hours. This is because doctors worry that IVT might cause dangerous bleeding in the brain. However, new research suggests that IVT might be safe for these patients. Some studies even show that stroke patients on FXa inhibitors who receive IVT do not have a higher risk of brain bleeding than other stroke patients. But because these studies were not designed as full medical trials, doctors still avoid IVT for this group. The SIFT trial will compare two groups of stroke patients who take FXa inhibitors: One group will receive IVT to see if it helps them recover better. One group will not receive IVT, which is the current standard. Doctors will check if IVT helps with recovery and if it causes any serious bleeding. If IVT is found to be safe and effective, this study could change stroke treatment guidelines and help more patients get life-saving care. Right now, some guidelines say that stroke patients on FXa inhibitors should have a blood test before getting IVT, to measure how much of the drug is in their system. But these tests are not available in most hospitals, and waiting for results could delay important treatment. The SIFT trial will not require this test before giving IVT. More and more people use FXa inhibitors to prevent strokes, but right now, they are being denied IVT based on old rules. If this study proves that IVT is safe for them, it could help doctors give better care to thousands of stroke patients.

Interventions

thrombolysis therapy (Drug)
All treatment and monitoring routines are according to the hospitals' standard operating procedures (SOP), and both drugs (Alteplase (ALP) and Tenecteplase (TNK)) are approved drugs for the indication AIS with similar efficacy and safety profile. SIFT is designed to test the hypothesis that intravenous thrombolysis (IVT) (tenecteplase 0.25 mg/kg or alteplase 0.9 mg/kg intravenously) is efficient and safe in acute ischemic stroke patients (AIS) with recent ingestion (last 48 hours) of an Factor Xa (FXa) inhibitor who otherwise are eligible for IVT.

Eligibility criteria

Inclusion Criteria: 1. Participant must be 18 years of age or older. 2. Ingestion of FXa inhibitors within the last 48 hours of symptom onset (or ongoing prescription of FXa inhibitor if unknown) 3. Clinical diagnosis of AIS with disabling neurological deficit 4. Presenting within 4.5 h of symptom onset or after awakening with symptoms of AIS with FLAIR-DWI mismatch on MRI as judged by the (neuro-) radiologist. 5. Informed consent Exclusion Criteria: 1. Endovascular treatment eligible patients with isolated large vessel occlusion of the intracranial internal carotid artery (ICA), the M1 segment of the middle cerebral artery (MCA), or both confirmed by CT or MR angiography and expected time from randomization to groin puncture of \<30 minutes. 2. Systolic BP \>185 mmHg or diastolic BP \>110 mmHg despite antihypertensive treatment. 3. Known bleeding diathesis; manifest or recent severe bleeding; significant bleeding disorder last 6 months. 4. Arterial puncture at a non-compressible site; biopsy or lumbar puncture \<7 days; major surgery, traumatic external heart massage, obstetrical delivery or serious trauma \<14 days; history of intracranial haemorrhage; stroke \<2 months, CNS neurosurgery \<2 months; serious head trauma \<2 months; pericarditis; sepsis; bacterial endocarditis; pericarditis; acute pancreatitis; neoplasm with increased bleeding risk; any serious medical illness likely to interact with treatment (i.e. aortic dissection); confounding pre-existent neurological or psychiatric disease. 5. Any condition that, in the opinion of the treating physician, puts a patient at risk if treated with thrombolysis (i.e. signs of cerebral hemorrhage, known cerebral amyloid angiopathy, CT with signs of early ischemia greater than one-third of the middle cerebral artery territory). Prior/Concomitant Therapy 6. Use of a) direct thrombin (II) inhibitor (Dabigatran) or b) warfarin with an INR ≥1.8; c) heparin \<48 h; d) treatment dose of LMWH \<24 h. Prior/Concurrent Clinical Study Experience 7. Hypersensitivity to Alteplase or Tenecteplase

Conditions

Stroke Stroke (in Patients With Atrial Fibrillation) Ischemic Stroke Acute Ischemic Stroke Anticoagulant Therapy Factor Xa Inhibitor Intracranial Hemorrhages Hemorrhagic Transformation Due to Acute Stroke Bleeding in the Brain

Locations

Dept. of Neurology, Aalborg Universitetshospital — Aalborg, Aalborg, Denmark
Dept of Neurology Aarhus University Hospital — Aarhus, Aarhus N, Denmark
Dept. of Medicine, Baerum Hospital — Baerum, Gjettum, Norway
Dept of Medicine, Helse More and Romsdal Health Trust, Aalesund Hospital — Ålesund, Norway
Dept of Medicine, Haraldsplass deaconal Hospital — Bergen, Norway
Dept. Of Neurology, Haukeland University Hopsital — Bergen, Norway
Dept of Neurology, Drammen Hospital Trust — Drammen, Norway
Dept of Neurology, Ostfold Hospital Trust, Kalnes — Grålum, Norway
Dept of Neurology, Hospital of Southern Norway, SSHF — Kristiansand, Norway
Dept of Neurology, Innlandet Hospital Trust, Lillehammer — Lillehammer, Norway
Dept. of Neurology, Oslo University Hospital — Oslo, Norway
Dept of Neurology, Stavanger University Hospital — Stavanger, Norway
Dept. of Neurology, Tromso University Hospital — Tromsø, Norway
Dept. Of Medicine, St.Olav Hospital, Trondheim — Trondheim, Norway
Dept of Neurology, Vesfold Hospital Trust, Tonsberg — Tønsberg, Norway
Dept of Neurology Danderyd Hospital — Stockholm, Danderyd, Sweden
Dept of Neurology , Lund University Hospital — Lund, Lund, Sweden
Dept of Neurology, Stroke Unit Skåne University Hospital — Malmö, Malmö, Sweden
Dept of Neurology, Karolinska University Hospital — Stockholm, Stockholm County, Sweden
Dept of Neurology Norrland University Hospital — Umeå, Umeå, Sweden
Dept of Neurology, Uppsala University Hospital — Uppsala, Uppsala County, Sweden

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment